Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ORAGENICS INC (OGEN)

Oragenics CMO to present ONP-002 concussion program at IPAC-RS forum on September 17

Neutral Impact 2 of 5 other Written later

Oragenics said its Chief Medical Officer, James P. Kelly, is scheduled to present on the ONP-002 intranasal concussion candidate at the IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026. The filing is a routine investor-relations update that furnishes the presentation and press release; it reports no new clinical data, financial results, or guidance.

Key points

  • Presentation scheduled for Session 4: Successful Case Studies at 9:40 AM ET on Thursday, September 17, 2026, in Jersey City, New Jersey
  • Presentation covers ONP-002 development, a Phase IIa feasibility trial enrolling at three sites in Australia, and the proposed U.S. clinical design framework
  • Company says its IND application submission is anticipated in Q4 2026

The filing

CompanyORAGENICS INC (OGEN)
Form8-K, current report
Filed with the SECSep 16, 2026, 8:30 AM ET
Accession number0001493152-26-042843

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.